Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47 phox-/- mouse model of chronic granulomatous disease

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 2, 2006, Pages 422-427

  Dennis, Carly G ^a   Greco, William R ^a   Brun, Yseult ^a   Youn, Richard ^a   Slocum, Harry K ^a   Bernacki, Ralph J ^a   Lewis, Russell ^b   Wiederhold, Nathan ^b   Holland, Steven M ^c   Petraitiene, Ruta ^d   Walsh, Thomas J ^d   Segal, Brahm H ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; GALACTOMANNAN; MICAFUNGIN; PROTEIN P47; PROTEIN P47PHOX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BLOOD LEVEL; CHRONIC GRANULOMATOUS DISEASE; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; FUNGUS HYPHAE; HISTOLOGY; HISTOPATHOLOGY; INFECTION SENSITIVITY; KNOCKOUT MOUSE; LUNG; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SURVIVAL TIME;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DRUG THERAPY, COMBINATION; GRANULOMATOUS DISEASE, CHRONIC; LIPOPROTEINS; LUNG; MICE; NADPH OXIDASE; PEPTIDES, CYCLIC; PHOSPHOPROTEINS;

EID: 31944439000     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.2.422-427.2006     Document Type: Article

References (35)

1. Almyroudis, N. G., S. M. Holland, and B. H. Segal. 2005. Invasive aspergillosis in primary immunodeficiencies. Med. Mycol. Suppl. 43:S247-S259.
2. Balloy, V., M. Huerre, J. P. Latge, and M. Chignard. 2005. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect. Immun. 73:494-503.
3. Berenguer, J., M. C. Allende, J. W. Lee, K. Garrett, C. Lyman, N. M. Ali, J. Bacher, P. A. Pizzo, and T. J. Walsh. 1995. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone- induced immunosuppression. Am. J. Respir. Crit. Care Med. 152:1079-1086.
4. phox-/- mice. Infect. Immun. 73:5204-5207.
5. phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease. Blood 89:41-48.
6. Boutboul, F., C. Alberti, T. Leblanc, A. Sulahian, E. Gluckman, F. Derouin, and P. Ribaud. 2002. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin. Infect. Dis. 34:939-943.
7. Bowman, J. C., G. K. Abruzzo, J. W. Anderson, A. M. Flattery, C. J. Gill, V. B. Pikounis, D. M. Schmatz, P. A. Liberator, and C. M. Douglas. 2001. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother. 45:3474-3481.
8. Chandrasekar, P. H., J. L. Cutright, and E. K. Manavathu. 2004. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive aspergillosis. Clin. Microbiol. Infect. 10:925-928.
9. phox-/- mice. Implications for fungal pathogenicity and host defense in chronic granulomatous disease. J. Clin. Investig. 101:1843-1850.
10. Cohen, M. S., R. E. Isturiz, H. L. Malech, R. K. Root, C. M. Wilfert, L. Gutman, and R. H. Buckley. 1981. Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am. J. Med. 71:59-66.
11. Graybill, J. R., R. Bocanegra, G. M. Gonzalez, and L. K. Najvar. 2003. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J. Antimicrob. Chemother. 52:656-662.
12. phox mouse knock-out model of chronic granulomatous disease. J. Exp. Med. 182:751-758.
13. Kirkpatrick, W. R., S. Perea, B. J. Coco, and T. F. Patterson. 2002. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. 46:2564-2568.
14. Kontoyiannis, D. P., R. Hachem, R. E. Lewis, G. A. Rivero, H. A. Torres, J. Thornby, R. Champlin, H. Kantarjian, G. P. Bodey, and I. I. Raad. 2003. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98:292-299.
15. Luque, J. C., K. V. Clemons, and D. A. Stevens. 2003. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob. Agents Chemother. 47:1452-1455.
16. Maertens, J., A. Glasmacher, R. Herbrecht, M. Aoun, A. Thiebaut, C. Cordonnier, B. Segal, D. Caillot, C. Sable, J. Killar, A. Taylor, N. Kartsonis, and T. Patterson. 2005. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La., September 2005.
17. Marr, K. A., S. A. Balajee, L. McLaughlin, M. Tabouret, C. Bentsen, and T. J. Walsh. 2004. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J. Infect. Dis. 190:641-649.
18. Marr, K. A., M. Boeckh, R. A. Carter, H. W. Kim, and L. Corey. 2004. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39:797-802.
19. Nagai, H., J. Guo, H. Choi, and V. Kurup. 1995. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J. Infect. Dis. 172:1554-1560.
20. NCCLS. 2002. Reference methods for broth dilution antifungal susceptibility testing of filamentous fungi: approved standards, NCCLS document M38A. NCCLS, Wayne, Pa.
21. Petraitiene, R., V. Petraitis, A. H. Groll, T. Sein, S. Piscitelli, M. Candelario, A. Field-Ridley, N. Avila, J. Bacher, and T. J. Walsh. 2001. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob. Agents Chemother. 45:857-869.
22. Petraitis, V., R. Petraitiene, A. H. Groll, A, Bell, D. P. Callender, T. Sein, R. L. Schaufele, C. L. McMillian, J. Bacher, and T. J. Walsh. 1998. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 42:2898-2905.
23. Petraitis, V., R. Petraitiene, A. A. Sarafandi, A. M. Kelaher, C. A. Lyman, H. E. Casler, T. Sein, A. H. Groll, J. Bacher, N. A. Avila, and T. J. Walsh. 2003. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J. Infect. Dis. 187:1834-1843.
24. Pollock, J. D., D. A. Williams, M. A. Gifford, L. L. Li, X. Du, J. Fisherman, S. H. Orkin, C. M. Doerschuk, and M. C. Dinauer. 1995. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat. Genet. 9:202-209.
25. + flux. Nature 416:291-297.
26. Segal, B. H., and S. M. Holland. 2003. posting date. Invasive aspergillosis in chronic granulomatous disease. The Aspergillus Website. [Online.] http: //www.aspergillus.man.ac.uk.
27. Segal, B. H., and S. M. Holland. 2000. Primary phagocytic disorders of childhood. Pediatr. Clin. N. Am. 47:1311-1338.
28. Segal, B. H., T. L. Leto, J. I. Gallin, H. L. Malech, and S. M. Holland. 2000. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 79:170-200.
29. Sivak, O., K. Bartlett, V. Risovic, E. Choo, F. Marra, D. S. Batty, and K. M. Wasan. 2004. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis. J. Pharm. Sci. 93:1382-1389.
30. Te Dorsthorst, D. T. A., J. W. Mouton, C. J. P. van den Beukel, H. A. L. van der Lee, J. F. G. M. Meis, and P. E. Verweij. 2004. Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates. Antimicrob. Agents Chemother. 48:3147-3150.
31. Tkalcevic, J., M. Novelli, M. Phylactides, J. P. Iredale, A. W. Segal, and J. Roes. 2000. Impaired immunity and enhanced resistance to endotoxin in the absence of neutrophil elastase and cathepsin G. Immunity 12:201-210.
32. Walsh, T. J., R. L. Schaufele, T. Sein, J. Gea-Banacloche, M. Bishop, N. Young, R. Childs, J. Barrett, H. L. Malech, and S. M. Holland. 2002. Presented at the 40th annual meeting of the Infectious Disease Society of America, Chicago, Ill.
33. Warn, P. A., G. Morrissey, J. Morrissey, and D. W. Denning. 2003. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J. Antimicrob. Chemother. 51:913-919.
34. Warn, P. A., A. Sharp, J. Guinea, and D. W. Denning. 2004. Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole, and micafungin against Aspergillus and Candida. J. Antimicrob. Chemother. 53:743-749.
35. Wiederhold, N. P., D. P. Kontoyiannis, J. Chi, R. A. Prince, V. H. Tam, and R. E. Lewis. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. 190:1464-1471.